Exelixis Q3 2026 slides: CABOMETYX growth funds zanzalintinib push
Exelixis (EXEL) reported Q3 2026 revenue of $658.7M, up 10% YoY, with GAAP EPS of $0.85. CABOMETYX sales grew 11% YoY, while zanzalintinib, a key growth driver, is in seven label-enabling studies with FDA decision expected in early 2027. The company maintained full-year guidance and repurchased $249.9M in shares.
How this was made
The 30-second read
Why it matters
The presentation combines a fresh quarterly earnings datapoint with a defined regulatory milestone for the lead zanzalintinib NDA (PDUFA March 3, 2027), which can shift probability-weighted expectations for future revenue and valuation.
Market read
Traders can reassess near-term sentiment from the Q3 print and guidance, while longer-horizon positioning may hinge on the March 2027 FDA decision path for zanzalintinib in 3L+ mCRC.
What to watch
The article notes higher SG&A tied to launch preparation and legal/advisory fees; margin sensitivity and competitive dynamics in TKI and MSS mCRC could offset optimism if uptake or pricing underperforms.
Background
Exelixis is transitioning from a single-product focus (CABOMETYX/cabozantinib) to a multi-oncology-franchise platform centered on zanzalintinib, with multiple potentially label-enabling studies underway.
Ticker impact
Exelixis reported Q3 2026 revenue of $658.7M (+10% YoY) and maintained full-year 2026 guidance while advancing zanzalintinib toward an early-2027 regulatory decision.
Likely upward bias as investors price in sustained CABOMETYX growth and increased probability of zanzalintinib regulatory progress.
The article contains company-specific quarterly financials, capital return via buybacks, and a concrete FDA action date for the most advanced zanzalintinib program, which are direct drivers for near-term sentiment and forward expectations.
Market effects
Reinforces investor appetite for oncology franchise models where an established TKI cash flow funds multiple label-enabling studies.
Limited, primarily US biotech sentiment tied to FDA timeline expectations.
International franchise strength is highlighted via Ipsen royalties, supporting broader global oncology demand narratives.
Counterpoint
Despite strong CABOMETYX momentum, the stock’s longer-duration upside depends on zanzalintinib trial outcomes and FDA review risk, which can reprice quickly on any future readouts.
Key entities
- companyExelixis
NASDAQ-listed oncology biopharmaceutical company reporting Q3 2026 results and outlining zanzalintinib development and commercial readiness.
- productCABOMETYX
Cabozantinib franchise highlighted for continued market share gains and revenue growth.
- pipeline_assetzanzalintinib
Lead next-growth driver with Wave-1 studies and an FDA-accepted NDA for 3L+ metastatic colorectal cancer, PDUFA March 3, 2027.
- partnerIpsen
International partner referenced for cabozantinib royalties contributing to collaboration revenues.
- partnerMerck
Referenced as sponsor of combination studies evaluating zanzalintinib with belzutifan.
